Literature DB >> 8838704

Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome.

T L Katzenstein1, C Pedersen, C Nielsen, J D Lundgren, P H Jakobsen, J Gerstoft.   

Abstract

OBJECTIVE: To investigate the longitudinal changes in serum HIV RNA, and to clarify whether the viral load early in infection has a predictive value for the clinical outcome; also, to correlate viral phenotype at seroconversion and changes in CD4 cell counts with viral burden.
DESIGN: Twenty seroconverters with HIV isolates available at seroconversion had HIV RNA quantified by polymerase chain reaction (PCR) at seroconversion and thereafter every 6 months. Mean follow-up time was 65 months. Patients were classified according to viral phenotype at seroconversion, time to AIDS progression, serum viral load within the first year (less or more than 1.5 x 10(4) copies/ml).
RESULTS: High viral load at seroconversion was followed by a significant decline within the first months (P < 0.0005). Decline to < 1.5 x 10(4) copies/ml was correlated with slower progression to AIDS (P < 0.05). A correlation between the rate of CD4 decline and the median viral load during the ensuing viral load plateau phase was also shown (P < 0.05). Subsequent to this phase the viral burden increased. Rapid progressors had higher viral load than slow- or non-progressors; this was particularly pronounced late in infection. Harbouring syncytium-inducing (SI) virus at seroconversion was associated with faster progression to AIDS than non-SI (NSI; P < 0.005). The increased in vitro replication rate of SI over NSI was not translated into significantly higher serum HIV RNA.
CONCLUSION: Serum HIV RNA is high around the time of seroconversion. A significant decline within the first months hereafter is followed by a plateau phase, which in turn is followed by an increase in HIV RNA. HIV RNA early in infection has a predictive value for the clinical outcome. The increased virulence of SI over NSI virus did not translate into significantly higher HIV RNA values.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8838704     DOI: 10.1097/00002030-199602000-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  19 in total

1.  Comparison of levels of human immunodeficiency virus type 1 RNA in plasma as measured by the NucliSens nucleic acid sequence-based amplification and Quantiplex branched-DNA assays.

Authors:  C C Ginocchio; S Tetali; D Washburn; F Zhang; M H Kaplan
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

2.  Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population.

Authors:  A J Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

3.  Stability of human immunodeficiency virus RNA in blood specimens as measured by a commercial PCR-based assay.

Authors:  K Sebire; K McGavin; S Land; T Middleton; C Birch
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

4.  Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment.

Authors:  M Holodniy; L Rainen; S Herman; B Yen-Lieberman
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 5.  Antiretroviral therapy for human immunodeficiency virus infection in 1997.

Authors:  D A Katzenstein
Journal:  West J Med       Date:  1997-05

6.  Precise determination of time to reach viral load set point after acute HIV-1 infection.

Authors:  Xiaojie Huang; Hui Chen; Wei Li; Haiying Li; Xia Jin; Alan S Perelson; Zoe Fox; Tong Zhang; Xiaoning Xu; Hao Wu
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

7.  Small variations in multiple parameters account for wide variations in HIV-1 set-points: a novel modelling approach.

Authors:  V Müller; A F Marée; R J De Boer
Journal:  Proc Biol Sci       Date:  2001-02-07       Impact factor: 5.349

8.  Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival.

Authors:  A Watson; J Ranchalis; B Travis; J McClure; W Sutton; P R Johnson; S L Hu; N L Haigwood
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

9.  Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.

Authors:  Marlén M I Aasa-Chapman; Sophie Holuigue; Keith Aubin; Mailee Wong; Nicola A Jones; David Cornforth; Pierre Pellegrino; Philippa Newton; Ian Williams; Persephone Borrow; Aine McKnight
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

10.  Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques.

Authors:  Abdelkrim Mannioui; Olivier Bourry; Pierre Sellier; Benoit Delache; Patricia Brochard; Thibault Andrieu; Bruno Vaslin; Ingrid Karlsson; Pierre Roques; Roger Le Grand
Journal:  Retrovirology       Date:  2009-11-23       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.